NeuralBase's Acquisition of HeartEase Set to Transform Enterprise Wellness with AI-Powered Health Diagnostics
NeuralBase AI Ltd. announces its acquisition of HeartEase, an AI-powered diagnostic platform, aiming to revolutionize enterprise wellness and preventive health diagnostics by integrating smartphone-based heart health screening into its chatbot ecosystem.
NeuralBase AI Ltd. (OTC: NBBI), known for its enterprise brand BMP AI, has taken a significant step towards integrating wellness-focused, preventive healthcare solutions into its enterprise AI chatbot ecosystem by acquiring HeartEase. This AI-powered diagnostic platform utilizes smartphone microphones to detect early signs of heart abnormalities, offering a non-invasive, accessible, and real-time health screening tool. The acquisition underscores the growing demand from corporations for integrated employee wellness solutions that go beyond mental health chatbots to provide actionable health diagnostics.
HeartEase stands out by enabling heart health screening through mobile devices without the need for external hardware, making it a perfect complement to BMP AI’s enterprise-focused chatbot technology. Vighnesh Dobale, CEO of NeuralBase, highlighted the revolutionary potential of HeartEase, emphasizing its ability to harness artificial intelligence and mobile technology for early detection of heart abnormalities. The platform is designed for global accessibility, including low-resource settings, and prioritizes privacy with future updates aimed at offline diagnostic capabilities.
The integration of HeartEase into BMP AI’s chatbot platform represents a transformational shift in enterprise workforce care. By embedding preventive health screening into the daily digital experience on employees’ smartphones, NeuralBase is redefining how technology can protect and empower individuals in their everyday lives. The backend AI engine of HeartEase is already trained with validated clinical datasets, with a Minimum Viable Product (MVP) expected for field testing in Q4 2025. This move positions NeuralBase at the forefront of AI-driven preventive healthcare, offering businesses a unique competitive edge through lower healthcare costs and higher productivity and retention rates.
For more information on NeuralBase AI Ltd., visit https://www.neuralbase.ai or the SEC’s EDGAR database at https://www.sec.gov. The acquisition is subject to customary due diligence and closing conditions, with NeuralBase committed to providing further updates as they become available.